Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Stella Pharma's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4888 vs VRTX, REGN, MRNA: Buyback Yield % Comparison
For the Biotechnology subindustry, Stella Pharma's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stella Pharma Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stella Pharma's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Stella Pharma's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stella Pharma (TSE:4888) has a Buyback Yield % of 0.00 as of Sep. 07, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Stella Pharma and its competitors. According to the industry distribution chart, Stella Pharma ranks #999999 out of 699 companies in the Biotechnology industry.
Is Stella Pharma's Buyback Yield % too high?
Stella Pharma's current Buyback Yield % is 0.00. Based on the distribution chart, Stella Pharma ranks #999999 out of 699 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Stella Pharma has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Stella Pharma ranks #999999 out of 699 companies for Buyback Yield %. This places Stella Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Stella Pharma and its competitors. Stella Pharma's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Fairly Valued. The stock's GF Value™ is 円371.06, compared to a current price of 円370.00 — trading 0.3% below its estimated fair value. The current Buyback Yield % is 0.00. Stella Pharma's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current Buyback Yield % is 0.00 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stella Pharma (TSE:4888) Overvalued in 2026?
Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued.
The current stock price of 円370.00 is trading 0.3% below its estimated GF Value™ of 円371.06.
GuruFocus considers Stella Pharma to be Fairly Valued.
Key valuation signals for TSE:4888:
Buyback Yield %: 0.00
GF Value™: 円371.06 vs. price of 円370.00 (0.3% below fair value)
No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
77GF Score
Get the complete analysis for TSE:4888
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4888 has been successfully added to your 
